1 H-NMR-based urine metabolomics of prostate cancer and benign prostatic hyperplasia.
| Autor: | Zniber M; Laboratory of Molecular Science and Engineering, Åbo Akademi University, Turku, Finland., Lamminen T; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Taimen P; Institute of Biomedicine and FICAN West Cancer Centre, University of Turku and Department of Pathology, Turku University Hospital, Turku, Finland., Boström PJ; Department of Urology, University of Turku and Turku University Hospital, Turku, Finland., Huynh TP; Laboratory of Molecular Science and Engineering, Åbo Akademi University, Turku, Finland. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Heliyon [Heliyon] 2024 Mar 31; Vol. 10 (7), pp. e28949. Date of Electronic Publication: 2024 Mar 31 (Print Publication: 2024). |
| DOI: | 10.1016/j.heliyon.2024.e28949 |
| Abstrakt: | Background: Prostate cancer (PCa) and benign prostatic hyperplasia (BPH) are prevalent conditions affecting a significant portion of the male population, particularly with advancing age. Traditional diagnostic methods, such as digital rectal examination (DRE) and prostate-specific antigen (PSA) tests, have limitations in specificity and sensitivity, leading to potential overdiagnosis and unnecessary biopsies. Significance: This study explores the effectiveness of 1 H NMR urine metabolomics in distinguishing PCa from BPH and in differentiating various PCa grades, presenting a non-invasive diagnostic alternative with the potential to enhance early detection and patient-specific treatment strategies. Results: The study demonstrated the capability of 1 H NMR urine metabolomics in detecting distinct metabolic profiles between PCa and BPH, as well as among different Gleason grade groups. Notably, this method surpassed the PSA test in distinguishing PCa from BPH. Untargeted metabolomics analysis also revealed several metabolites with varying relative concentrations between PCa and BPH cases, suggesting potential biomarkers for these conditions. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|